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A B S T R A C T
Conventional aortic valve replacement in patients with porcelain aorta can be techni-
cally challenging and is even sometimes seen as contraindication. Trans-aortic valve 
implantation has been proposed as an alternative to other trancutaneous routes of 
implantation and is feasible when there is a small healthy area in the right anterolat-
eral aspect of the ascending aorta. Herein we report an interesting case of combined 
transaortic valve implantation and off-pump coronary artery bypass grafting in a pa-
tient with severe aortic stenosis, severe ostial left main coronary artery disease and 
porcelain aorta.
I n T R o d u C T I o n 
The surgical AVR or/and CABG surgery in patients with “porcelain” ascending 
aorta (PAA) is associated with increased morbidity/mortality and remains controver-
sial.1 TAVI is the procedure of choice for the management of patients with severe 
symptomatic aortic stenosis at high (class I indication) and intermediate (class IIa indi-
cation) operative risk for traditional surgical AVR.2,3 TAVI using the Edwards SAPIEN 
XT device (Edwards LifeScience, Irvine, CA) is usually performed via retrograde, or 
apical approach.4 TAo-AVI has been also described as a safe and feasible alternative 
retrograde approach that can avoid complications related to the access route.5 
Although PAA can be a relative contraindication to TAo-AVI approach, however 
a small calcification free spot of the aortic wall can be sufficient to achieve secure 
insertion of the devices. Herein we report an interesting case of combined TAo-AVI 
with off-pump CABG surgery in a patient with severe aortic stenosis, left main CAD 
and PA via a median sternotomy.
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C A S e  R e p o R T
A 70-year-old female patient with history of severe 
symptomatic (NYHA-III, CCS II) aortic stenosis (Aortic 
Valve Area 0.7cm2 and mean transvalvular pressure gradient 
40mmHg) was referred for TAVI. The annulus was meas-
ured at 18mm by Transesophageal Echocardiography. Her 
past medical history included anterior myocardial infarction 
successfully treated with primary angioplasty, arterial hy-
pertension, dyslipidemia and insulin independent diabetes 
mellitus. Also, she had a history of breast cancer successfully 
treated with surgery and radiation. Coronary angiography and 
aortography revealed a significant ostial left main CAD with 
no instent restenosis in the Left Anterior Descending artery 
(LAD) stent, and a PAA, respectively (Figure 1). CT thorax 
scan confirmed the severe calcification of the ascending aorta, 
with a calcified free segment at approximately 50mm above 
the annulus (Figure 2).  
Appropriate management of coexistent CAD in TAVI 
patients is yet to be defined. Calcified aorto-ostial lesions 
requiring rotational atherectomy may pose a particular chal-
lenge for PCI post TAVI, when interaction of the rotablation 
system and the TAVI frame is possible. The solution of BAV 
followed with LM PCI could be an option. Atherectomy 
of aorto- ostial LM CAD in patients with PAA is feasible 
however is correlated with high rate of complications and 
low technical success.6 Since the patient was of low surgical 
risk (estimated logistic Euroscore-I 4.2% and STS mortality 
score 2.2%) and there was a calcified free segment at ascend-
ing aorta, the “Heart Team” decided to perform CABG via 
a median sternotomy combined with TAo-AVI in order to 
avoid the secondary anterior left thoracotomy and the Trans-
Apical Aortic Valve Implantation (TAp-AVI) access route 
associated complications.
The procedure was performed in hybrid room with the 
patient placed in supine position and under general anesthe-
sia. After median sternotomy the LIMA was dissected in a 
skeletonized manner. The heart was exposed and positioned 
for off-pump CABG. The LIMA was grafted in an end-to-
side fashion onto the LAD, without complications and with 
good TIMI flow. Subsequently, a calcification free spot at 
the right anteroseptal aspect of the ascending aorta (ap-
proximately 50mm from the annulus) was chosen for access 
site, after careful manually and echocardiographic evaluation. 
Puncturing of the ascending aorta was performed through 
a 6F catheter. The aortic valve was crossed with a soft wire. 
An extra stiff wire was introduced into the LV after cross-
ing the aortic valve with an Amplatz Left 2 catheter. The 
Ascendra 16F sheath was then directly introduced through 
the purse-string sutures and was kept in the upper part of 
the ascending aorta. The proximity between the puncture site 
in the ascending aorta and the aortic valve created a stable 
straightforward platform for the procedure. Aortic valve 
orifice area enlargement was performed by BAV, inflating 
a 20mm balloon for 15 seconds. Then, a 23mm Sapien XT 
FIguRe 1. Coronary angiography (spider view) showing signifi-
cant ostial left main disease.
FIguRe 2. CT scan demonstrating the severe calcification of 
the ascending aorta, “porcelain”, with a calcified free segment 
at the right anteroseptal aspect of the ascending aorta, approxi-
mately 50mm above the annulus.
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FIguRe 3. A. Aortic valve orifice area enlargement was performed by BAV, inflating a 20mm balloon for 15 seconds. B. 23mm 
Edwards Sapien device (Edwards LifeScience, Irvine, CA) was successfully implanted, by balloon inflation.
A. B.
FIguRe 4. A-B. Transesophageal Echocardiography immediately post implantation showing satisfactory valve position and function 
with mild paravalvular leak.
A. B.
device was successfully implanted under rapid pacing. Both, 
BAV and TAo-AVI were performed, while the patient was 
paced at a ventricular rate of 180 beats/minute, (Figure 3A, 
3B). An intraoperative Transesophageal Echocardiography 
confirmed the correct positioning and functioning of the bio-
prosthetic valve indicating a mild paravalvular leak (Figure 
4A, 4B). The Ascendra-2 sheath was withdrawn and hemosta-
sis was achieved. The sternum was closed with 6 steel wires. 
The operation lasted 180 minutes in total, the fluoroscopy 
time was 11:29 minutes, the dose-area product (DAP) was 
369.592 cGycm2 and the contrast agent (Visipaque) volume 
was 150ml.
Postoperatively, the patient was transferred to the intensive 
care unit, where she was extubated after 16 hours without 
neurological complications. The patient was transferred to 
normal station after 32h. The postoperative course of our pa-
tient was complicated by atrial fibrillation successfully treated 
with i.v amiodarone. She was discharged in sinus rhythm on the 
8th postoperative day. His convalescence at home remained 
uneventful.
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d I S C u S S I o n
Aortic valve stenosis is the most frequent acquired heart 
valve disease and has well defined surgical indications.1 Al-
though the technique of median sternotomy, cardiopulmonary 
bypass and cardioplegic arrest remains the gold standard for 
conventional AVR, this may prove a high-risk procedure 
in patients with PAA.7 Patients with severe aortic stenosis 
considered unsuitable for surgical AVR had better outcomes 
with TAVI compared to medical treatment.2 TAVI using 
the Edwards SAPIEN device (Edwards LifeScience, Irvine, 
CA) is usually performed via retrograde (TF or Subclavian, 
or Transapical). The SOURCE Registry (Sapien Aortic Bio-
prosthesis European Outcome) show a 9% 30-day mortality in 
TAp-AVI patients, mainly due to major access complications.8 
TAo-AVI was described for both most commonly used bal-
loon and self-expandable devices as a new, safe and feasible 
alternative retrograde approach that can avoid complications 
related to the access route.8,9,10
Combined TAp-AVI with CABG surgery in a patient with 
PAA has been reported.11 In our case, the option to perform 
an off-pump LIMA-LAD bypass via a median sternotomy 
combined with TAp-AVI via a secondary anterior left thora-
cotomy was rejected since there was a high risk for prolonged 
hospitalization and subsequent apical-wall-motion abnor-
malities. In contrast, TAo-AVI could be accomplished easily 
sequel after the LIMA-LAD bypass via the existing median 
sternotomy, thus decreasing the risk of access complications.5
TAp-AVI carries specific risks inherent to the access 
route. Echocardiographic data indicate that after TAp-AVI 
approximately 33% of the patients developed new apical hypo- 
or akinesia, affecting the LVEF in 7–13% of the patients.10 
This is significant in patients with a very low LVEF where 
additional scarring on the apex can adversely affect postop-
erative prognosis. Also, TAp-AVI carries relative high risk of 
severe bleeding, postprocedural re-exploration and aneurysm 
formation, significantly impairing the survival.12,13 In the above 
mentioned retrospective study severe apical bleeding requiring 
extracorporeal bypass and/or complete sternotomy, termina-
tion of the procedure without valve implantation, or surgical 
re-exploration was detected in 7% of the cases.12 In contrast, 
after TAo-AVI, hemostasis can be easily completed after 
withdrawal of catheters, even in fragile aortas.5   
However, TAo-AVI involves some manipulation of the 
ascending aorta increasing the risk of periprocedural em-
bolism and cerebrovascular accident. Although PAA can be 
a contraindication to TAo-AVI approach, however a small 
calcification-free spot of the anterior aortic wall can be suf-
ficient to achieve secure insertion of the devices.5 Moreover, in 
comparison with the TF approach, manipulation of the aortic 
arch is avoided, which is known to be the primary source of 
atherosclerotic emboli.14 Therefore, with a careful manual and 
imaging examination of the ascending aorta, the subsequent 
risk of stroke can be minimized.  
Although TAp-AVI approach via an anterior minithora-
cotomy is technically feasible is undesirable in patients with 
severe chest deformity, poor lung function, previous pulmonary 
complications and poor LVEF. In contrast, TAo-AVI can be 
performed through an upper ministernotmy. The upper minis-
ternotomy has advantages with respect to respiratory function, 
due to preservation of the diaphragm, postoperative bleeding 
and postoperative pain.5,15 Also, TAo-AVI avoids opening the 
left pleura and the subsequent necessity for pleural drainage, 
compared with the TAp-AVI. In addition, the upper minis-
ternotmoy can be easily converted to full sternotomy in case 
of catastrophic complications, such as annular rupture, valve 
migration, coronary ostia obstruction, allowing prompt access 
for conventional surgery. However, a technical consideration of 
the upper ministernotomy TAo-AVI approach can be patients 
with patent vein grafts or with the right internal thoracic artery 
crossing anteriorly the aorta.
Recently, it was shown that alternate access options that 
mimic the results of TF-TAVI avoiding morbidity of transtho-
racic approaches are: [A] the Trans-Carotid approach, which 
has as a main contraindication the existence of more than 
50% stenosis in the common or internal carotids, congenital 
variants, prior instrumentation, and contralateral carotid 
occlusion or vertebral stenosis. In addition requires arteries 
greater than 7mm and evaluation with Brain MRI angiography 
and transcranial Doppler. Recent propensity match analysis 
comparing transcarotid with transapical and transaortic ac-
cess clearly showed that the former is correlated with shorter 
length of stay, fewer transfusions, more frequent discharge to 
home, and better 2-year survival,16 [B] Transcaval approach, 
the most novel alternative access route for TAVI, requires 
specialized experience and involves femoral vein access with 
crossover to the abdominal aorta from the inferior vena cava. 
Periprocedural CT scanning is of paramount importance to 
ensure that there is a suitable non-calcified area of abdominal 
aorta to allow wire crossover from the inferior vena cava. This 
area of aorta should be free of any important arterial branches, 
such as the renal artery, renal vein and aorto-iliac bifurcation, 
as a covered stent may be required as a bailout strategy if there 
are bleeding complications during the procedure. Recent 
European data are encouraging with this approach regarding 
safety and feasibility,17 and [C] Trans-subclavian or axillary 
approach requires size of the arteries ≥ 6 mm. Although 
majority of trans-subclavian cases performed via the left sub-
clavian artery in case of LIMA-LAD graft we prefer no to use 
it avoiding potential ischemia or injury of LIMA graft. Right 
subclavian artery is used exceptionally due to its inconvenient 
implantation angle. Recent report showed that the stroke risk 
with both balloon-expandable and self-expanding valves when 
delivered transaxillary is relative high (5-6%) [18]. Therefore, 
although there are other access site options in case of TF-TAVI 
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contraindication, selection of the approach should be highly 
individual based on the experience of the “Heart Team”, 
the availability of different valve types, and the anatomy and 
pathology of the patient’s vessels. In addition, ongoing follow-
up of patients treated with this approaches and future studies 
needed to determine the long-term outcomes. In our case the 
“heart team” was familiar with the transaortic approach and 
the PAA had a free of calcium spot therefore the decision was 
to combined TAo-TAVI with CABG.
C o n C L u S I o n
In conclusion, TAo-AVI using Edwards Sapien Valve 
can be feasible in patients with aortic valve stenosis and PAA 
undergoing off pump CABG surgery via a median sternotomy. 
However, the presence of “porcelain” ascending aorta requires 
careful manual and imaging examination. Furthermore, TAo-
AVI through an upper ministernotomy, provides an alternative 
feasible option especially in patients deemed unsuitable for 
conventional approaches.
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